Antibacterial Drugs Market Development, Trends, Segmentations Analysis

According to Transparency Market Research’s latest report on the global antibacterial drugs market for the historical period 2017–2018 and forecast period 2019–2027, high prevalence of infectious diseases, increase in research and developmental activities, and increase in initiatives by government in healthcare sector are the factors projected to drive the global antibacterial drugs market during the forecast period
According to the report, the global antibacterial drugs market was valued at US$ 46.37 Bn in 2018 and is anticipated to expand at a CAGR of 1.5% from 2019 to 2027

Request the Coronavirus Impact Analysis on this Markets - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1567

To know the scope of our report Get a Sample on Antibacterial Drugs Market

Increase in Prevalence of Infectious Diseases: Key Driver

High prevalence of infectious diseases results in increasing number of patient population and rise in the demand for antibacterial drugs, which thereby is responsible for driving the antibacterial drugs market
According to Baylor College of Medicine, infectious diseases are a leading cause of death worldwide, particularly in low income countries, especially in young children.
European Centre for Disease Prevention and Control (ECDC) states that, every year, around three million people in the EU catch a healthcare-associated infection, of whom approximately 50,000 die.
According to National Hospital Ambulatory Medical Care Survey in 2016 in U.S., approximately 280,000, emergency department visits resulted in hospital admission with a principal hospital discharge diagnosis of infectious and parasitic diseases

Get a glimpse of the in-depth analysis through our Report Brochure

Increase in geriartic population and increasing number of antibiotic resistance or multi-drug resistant bacterial strains

According to a study published in 2016, titled “Infection in an aging population”, the global population is rapidly aging. Currently, 566 million people are 65 years old worldwide, with estimates of nearly 1.5 billion by 2050, particularly in developing countries. Infections constitute a third of mortality in people 65 years old. Moreover, lengthening life spans correlate with increased time in hospitals or long-term care facilities and exposure to drug-resistant pathogens. Indeed, the risk of nosocomial infections increases with age, independent of duration spent in healthcare facilities.
According to WHO, antibiotic resistant bacteria are responsible for up to 60% of hospital acquired infections in the United States. Resistance means that people with infections are ill for longer periods, and are at greater risk of dying, and that disease epidemics are prolonged.
As per WHO, in 2016, around 490,000 people developed multi-drug resistant tuberculosis globally, and drug resistance is starting to complicate the fight against HIV and malaria, as well.
Therefore, rise in geriatric population, and increasing number of antibiotic resistance or multi-drug resistant bacterial strains are responsible for boosting the growth of the antibacterial drugs market

Buy _ Research Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1567&ltype=S

Rising number of generic drugs for antibacterial activities and patent expiries to Hamper Market

The Generic Drug User Fee Amendments (GDUFA), passed by U.S. Congress in 2012, were intended to speed U.S. Food and Drug Administration approval of new generic drugs, which create competition for brand drugs and reduce drug prices for consumers.
Wide availability of over the counter (OTC) drugs and generic drugs, and number of antibacterial drugs near to off patent is anticipated to lead to a shift from branded drugs to generic ones, which could hamper the antibacterial drugs market from realizing its true revenue potential.
Henceforth, above mentioned factors can thereby hamper the growth of the antibacterial drugs market

Expanding operations in future? To get the perfect launch ask for a custom report

Global Antibacterial Drugs Market: Competitive Landscape

This report profiles major players in the global antibacterial drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global antibacterial drugs market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global antibacterial drugs market are

Bayer AG
Pfizer Inc.
Sanofi
GlaxoSmithKline plc.
Merck & Co., Inc.
AstraZeneca
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb Company
Novartis AG
Allergan,

Global Antibacterial Drugs Market: Key Developments

Key players in the global antibacterial drugs market are engaged in regulatory approvals, new drug developemnt, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global antibacterial drugs market. A few expansion strategies adopted by players operating in the global antibacterial drugs market are:

In October 2019, GSK started a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin
In July 2019, the FDA approved new triple-drug antibiotic from Merck, Recarbrio (imipenem, cilastatin, relebactam) for injection, 1.25 gm for the treatment of patients at least 18 years old with complicated urinary tract infections, including pyelonephritis, and complicated intra abdominal infections caused by certain Gram-negative bacteria who have limited or no alternative treatment options.
In August 2016, Pfizer Inc. announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infectives business, primarily outside the United States.

More Trending Reports by Transparency Market Research – https://www.biospace.com/article/advances-in-nanotechnology-drug-delivery-models-to-create-new-paradigms-in-cancer-therapeutics/